We are live on ! Find out more
MGRX icon

Mangoceuticals

11 hedge funds and large institutions have $820K invested in Mangoceuticals in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

85% more capital invested

Capital invested by funds: $444K → $820K (+$376K)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

10% more funds holding

Funds holding: 10 → 11 (+1)

0.53% more ownership

Funds ownership: 2.75% → 3.28% (+0.53%)

Holders
11
Holders Change
+1
Holders Change %
+10%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MGRX Hedge Fund Activity: Q3 2025 in Review

11 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q3 2025, worth a combined $820K — up 85% from $444K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new MGRX positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $115K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $47.1K sold.

  • 11 institutional investors held Mangoceuticals (MGRX) as of Q3 2025, up from 10 in Q2 2025.
  • Funds reported $820K of Mangoceuticals stock for Q3 2025, up 85% quarter-over-quarter.
  • 4 funds opened new Mangoceuticals positions in Q3 2025 and 3 closed out, a net change of +1 holder.
  • The largest Mangoceuticals buyer in Q3 2025 was Geode Capital Management, an estimated $115K added.
  • The largest Mangoceuticals seller in Q3 2025 was Renaissance Technologies, an estimated $47.1K sold.

Based on aggregated 13F filings for Q3 2025.